OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
December 01, 2023
Retina specialists discuss treatment and adherence strategies for patients with nAMD and DME. They also comment on the future of nAMD and DME management.
Retina specialists discuss factors to consider when selecting a therapy for patients with neovascular AMD and DME as well as loading-dose recommendations for select patients.
Retina specialists comment on switching patients from 2 mg to 8 mg of aflibercept for the management of neovascular age-related macular degeneration and diabetic macular edema and transitioning a patient who has good control with aflibercept to a newer therapy.
November 24, 2023
Rishi P. Singh, MD; and Michael A. Klufas, MD, discuss how to gain both physician and patient trust when it comes to using biosimilars to treat ophthalmologic conditions.